R E Pataky1, C R Baliski2. 1. Canadian Centre for Applied Research in Cancer Control, BC Cancer Agency, Vancouver. 2. Surgical Oncology, Sindi Ahluwalia Hawkins Centre for the Southern Interior, BC Cancer Agency, Kelowna, University of British Columbia, Vancouver, BC; Department of Surgery, University of British Columbia, Vancouver, BC.
Abstract
BACKGROUND: Breast-conserving surgery (bcs) is the preferred surgical approach for most patients with early-stage breast cancer. Frequently, concerns arise about the pathologic margin status, resulting in an average reoperation rate of 23% in Canada. No consensus has been reached about the ideal reoperation rate, although 10% has been suggested as a target. Upon undergoing reoperation, many patients choose mastectomy and breast reconstruction, which add to the morbidity and cost of patient care. We attempted to identify the cost of reoperation after bcs, and the effect that a reduction in the reoperation rate could have on the B.C. health care system. METHODS: A decision tree was constructed to estimate the average cost per patient undergoing initial bcs with two reoperation frequency scenarios: 23% and 10%. The model included the direct medical costs from the perspective of the B.C. health care system for the most common surgical treatment options, including breast reconstruction and postoperative radiation therapy. RESULTS: Costs ranged from a low of $8,225 per patient with definitive bcs [95% confidence interval (ci): $8,061 to $8,383] to a high of $26,026 for reoperation with mastectomy and delayed reconstruction (95% ci: $23,991 to $28,122). If the reoperation rate could be reduced to 10%, the average saving would be $1,055 per patient undergoing attempted bcs (95% ci: $959 to $1,156). If the lower rate were to be achieved in British Columbia, it would translate into a savings of $1.9 million annually. SUMMARY: The implementation of initiatives to reduce reoperation after bcs could result in significant savings to the health care system, while potentially improving the quality of patient care.
BACKGROUND: Breast-conserving surgery (bcs) is the preferred surgical approach for most patients with early-stage breast cancer. Frequently, concerns arise about the pathologic margin status, resulting in an average reoperation rate of 23% in Canada. No consensus has been reached about the ideal reoperation rate, although 10% has been suggested as a target. Upon undergoing reoperation, many patients choose mastectomy and breast reconstruction, which add to the morbidity and cost of patient care. We attempted to identify the cost of reoperation after bcs, and the effect that a reduction in the reoperation rate could have on the B.C. health care system. METHODS: A decision tree was constructed to estimate the average cost per patient undergoing initial bcs with two reoperation frequency scenarios: 23% and 10%. The model included the direct medical costs from the perspective of the B.C. health care system for the most common surgical treatment options, including breast reconstruction and postoperative radiation therapy. RESULTS: Costs ranged from a low of $8,225 per patient with definitive bcs [95% confidence interval (ci): $8,061 to $8,383] to a high of $26,026 for reoperation with mastectomy and delayed reconstruction (95% ci: $23,991 to $28,122). If the reoperation rate could be reduced to 10%, the average saving would be $1,055 per patient undergoing attempted bcs (95% ci: $959 to $1,156). If the lower rate were to be achieved in British Columbia, it would translate into a savings of $1.9 million annually. SUMMARY: The implementation of initiatives to reduce reoperation after bcs could result in significant savings to the health care system, while potentially improving the quality of patient care.
Entities:
Keywords:
Breast cancer; breast-conserving surgery; costs; mastectomy; quality of care
Authors: Lee G Wilke; Tomasz Czechura; Chih Wang; Brittany Lapin; Erik Liederbach; David P Winchester; Katharine Yao Journal: JAMA Surg Date: 2014-12 Impact factor: 14.766
Authors: Nicole M A Krekel; Max H Haloua; Alexander M F Lopes Cardozo; Roos H de Wit; Anne Marie Bosch; Louise M de Widt-Levert; Sandra Muller; Henk van der Veen; Elisabeth Bergers; Elly S M de Lange de Klerk; Sybren Meijer; M Petrousjka van den Tol Journal: Lancet Oncol Date: 2012-12-04 Impact factor: 41.316
Authors: D E Wazer; T DiPetrillo; R Schmidt-Ullrich; L Weld; T J Smith; D J Marchant; N J Robert Journal: J Clin Oncol Date: 1992-03 Impact factor: 44.544
Authors: R Jeevan; D A Cromwell; M Trivella; G Lawrence; O Kearins; J Pereira; C Sheppard; C M Caddy; J H P van der Meulen Journal: BMJ Date: 2012-07-12
Authors: Elvira L Vos; Sabine Siesling; Margreet H A Baaijens; Cornelis Verhoef; Agnes Jager; Adri C Voogd; Linetta B Koppert Journal: Breast Cancer Res Treat Date: 2017-04-07 Impact factor: 4.872
Authors: Lisanne L de Boer; Esther Kho; Koen K Van de Vijver; Marie-Jeanne T F D Vranken Peeters; Frederieke van Duijnhoven; Benno H W Hendriks; Henricus J C M Sterenborg; Theo J M Ruers Journal: Breast Cancer Res Date: 2021-05-22 Impact factor: 6.466
Authors: Caroline F Illmann; Christopher Doherty; Margaret Wheelock; Joshua Vorstenbosch; Joan E Lipa; Toni Zhong; Kathryn V Isaac Journal: Plast Surg (Oakv) Date: 2021-07-08 Impact factor: 0.947
Authors: Kathryn Ottolino-Perry; Anam Shahid; Stephanie DeLuca; Viktor Son; Mayleen Sukhram; Fannong Meng; Zhihui Amy Liu; Sara Rapic; Nayana Thalanki Anantha; Shirley C Wang; Emilie Chamma; Christopher Gibson; Philip J Medeiros; Safa Majeed; Ashley Chu; Olivia Wignall; Alessandra Pizzolato; Cheryl F Rosen; Liis Lindvere Teene; Danielle Starr-Dunham; Iris Kulbatski; Tony Panzarella; Susan J Done; Alexandra M Easson; Wey L Leong; Ralph S DaCosta Journal: Breast Cancer Res Date: 2021-07-12 Impact factor: 6.466
Authors: Marina T van Leeuwen; Michael O Falster; Claire M Vajdic; Philip J Crowe; Sanja Lujic; Elizabeth Klaes; Louisa Jorm; Art Sedrakyan Journal: BMJ Open Date: 2018-04-10 Impact factor: 2.692